Navigation Links
Bioniche Reports Fiscal 2007 Year-End Results
Date:9/26/2007

- consolidated revenues rise 3% over Fiscal 2006 to $27.5 million -

(all figures are in Canadian dollars unless otherwise noted)

BELLEVILLE, ON, Sept. 26 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2007 fiscal year ended June 30, 2007.

"The recent announcements of the first shipment and commercial usage of our E. coli O157:H7 cattle vaccine and the Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration for our second Phase III pivotal trial in bladder cancer occurred after the end of Fiscal 2007, but are the result of significant internal efforts during the fiscal year," noted Patrick Montpetit, Chief Financial Officer of Bioniche Life Sciences Inc. "During Fiscal 2007, we started our first Phase III clinical trial using our proprietary Mycobacterial Cell Wall-DNA Complex (MCC) in the treatment of bladder cancer patients whose condition is refractory (unresponsive) to the current standard therapy. We also closed a $17.5 million equity financing, with strong support from both institutional and individual investors."

Fiscal 2007 Financial Results Highlights

Consolidated revenues for the fiscal year increased by 3% to $27.5 million, as compared to $26.7 million in Fiscal 2006. The overall gross profit margin was 56% this fiscal year as compared to 57% in Fiscal 2006.

Expenses totalled $18.5 million for the 12 months ending June 30, 2007, which compares to $19.6 million recorded in the same period last year. This decrease of $1.1 million, or 6%, includes a decrease in interest on long-term debt and other interest associated with the refinancing and repayment of the Company's debt.

Gross research and development (R&D) expenses increased $2 million, or 16%, in Fiscal 2007, reaching $14.9 million compared to $12.9 million in Fiscal 2006. This is largely at
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Eckert & Ziegler Vitalea ... (AMS) services to the pharmaceutical and biotech industry, has ... company in the position of Director of Science & ... and valuable experience in drug metabolism and bioanalysis to ...
(Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2
... at the Diabetes... -- JERUSALEM, November 15, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... Kienberger received the 2010 ICO Prize for pioneering contributions ... this new scientific discipline is to capture snapshots of ... to yield important insights into the actual course of ... and the interactions between light and matter. "An ...
... CAMBRIDGE, Massachusetts, November 12, 2010 ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology Technology:Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 2Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 3Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 4Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 5Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 6Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 7Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 8Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD 92010 ICO Prize is awarded to TUM physicist Reinhard Kienberger 2Cell Press Delivers the News 2Cell Press Delivers the News 3Cell Press Delivers the News 4Cell Press Delivers the News 5Cell Press Delivers the News 6Cell Press Delivers the News 7
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... Crop Science Society of America (CSSA) announces the following 2012 ... Oct. 21-24, 2012 in Cincinnati, OH. Members of the Society ... service. Only 0.3 percent of the Society,s active and emeritus ... Fellows are: Marc C. Albertsen, Dupont Pioneer - ...
... must account for the complexity of the human impact ... and temporal scales. "Scale-sensitive research" emerges as a new, ... analyses, and tools to the scale in which these ... that the decisions they take resolve ecological problems at ...
... - When Washington State University and U.S. Department of Agriculture ... a rare but deadly infection was discovered among a group ... adrenaline. Not only were the horses infected with a parasitic ... the outbreak was at no ordinary ranch. It ...
Cached Biology News:Crop Science Society of America presents 2012 class of fellows 2Crop Science Society of America presents 2012 class of fellows 3Scientists call policy-makers to be scale-aware 2Scientists call policy-makers to be scale-aware 3WSU/USDA scientist creates test, treatment for malaria-like sickness in horses 2WSU/USDA scientist creates test, treatment for malaria-like sickness in horses 3WSU/USDA scientist creates test, treatment for malaria-like sickness in horses 4
... low background ,This solution greatly enhances antigen-antibody ... than obtained with conventional methods. ,Two kinds ... secondary antibodies, which can suppress the background ... Wide versatility ,It is applicable to various ...
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Biology Products: